http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100307069-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00 |
| filingDate | 1998-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100307069-B1 |
| titleOfInvention | Inhibition of Engiogenin and Plasmin |
| abstract | The present invention relates to inhibitors of angiogenin and plasmin. More specifically, the present invention relates to a chANG peptide (a gene codon corresponding to a base sequence encoding amino acids 58 to 68 of human engiogenin, reported as an inhibitor of angiogenin inducing renal angiogenesis. Peptide consisting of amino acids translated from anticodon (see patent application 97-44681) and specific deletion peptides derived therefrom and methods for inhibiting renal angiogenesis using the same The peptides of the present invention are renal angiogenesis and cancer cells It inhibits the activity of plasmin, which is essential for metastasis, and inhibits neovascularization induced by engiogenin and human cancer cells without affecting existing blood vessels. As a therapeutic agent for diseases such as rheumatoid arthritis, diabetic blindness and blindness due to macular degeneration of the retina Can be used effectively. |
| priorityDate | 1998-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.